C. elegans to accelerate industrial drug discovery and address the costs and challenges of early preclinical research

Magnitude Biosciences CEO, David Weinkove, discusses the application of C. elegans to accelerate the industrial drug discovery process at ELRIG and the British Pharmacological Society's event Translating Ideas Into Therapies 2021. You can also read our blog post summarising key takeaways from the other talks at the event: https://magnitudebiosciences.com/2021/07/09/elrig-bps-meeting-2021/

Contact us if you'd like to find out if and how we can help you with your drug discovery research